secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001213900-25-076633
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell swings to Q2 profit of $502k on 18% sales growth to $6.4M
------------------------------------------------------------------

- Q2 product sales $6.4M, up 18% YoY; H1 sales $14.5M, up 14%.
- Net income $502k ($0.06/diluted) vs loss of ($1.5M) in Q2 2024.
- Gross margin improved to 44% from 22%; adjusted EBITDA $1.4M in Q2.
- Cash rose to $6.0M from $3.8M at Dec 2024; no line-of-credit draws.
- Re-Tain: initiating field feedback, reducing R&D spend, exploring strategic options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390025076633/0001213900-25-076633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390025076633/ea0253265-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-076633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer